Peeters Peeters M M Smith Oliner Smith Oliner K K Price Price TJ TJ Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus folfiri for second-line treatment (tx) of metastatic colorectal cancer (mCRC) Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus folfiri for second-line treatment (tx) of metastatic colorectal cancer (mCRC) J Clin Oncol J Clin Oncol 2014 2014 32 32 5 5 3568 3568 10.1200/jco.2014.32.15_suppl.3568 10.1200/jco.2014.32.15_suppl.3568 25273035 25273035. Here, KRAS is linked to metastatic colorectal cancer.